CareDx agreed to acquire Naveris in a deal worth up to $260 million, giving it access to NavDx, a liquid biopsy test for HPV-related cancers. The acquisition adds tumor-naïve minimal residual disease (MRD) monitoring based on fragments of viral DNA in blood, a test that received Medicare coverage in 2023. CareDx said Naveris runs high-complexity CLIA laboratories in Massachusetts and North Carolina, with 2025 unaudited revenue of about $34 million and Q1 2026 revenue around $12 million. CareDx expects the business to grow 30% to 40% annually over the next three years and described the deal as a targeted move into a viral-mediated cancer space where longitudinal monitoring is reimbursed. The company plans additional validation work for NavDx in other HPV-driven settings, including MRD testing across additional gynecological cancer categories beyond current head-and-neck clinical use.